CoChat

Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents

Open access
Di Pino, Antonino, DeFronzo, Ralph A · 2019 · Endocrine Reviews

The DOI matches its Crossref record; 340 of the 344 references it cites were found in a registry or an index.

Abstract

Patients with type 2 diabetes mellitus (T2DM) are at high risk for macrovascular complications, which represent the major cause of mortality. Despite effective treatment of established cardiovascular (CV) risk factors (dyslipidemia, hypertension, procoagulant state), there remains a significant amount of unexplained CV risk. Insulin resistance is associated with a cluster of cardiometabolic risk factors known collectively as the insulin resistance (metabolic) syndrome (IRS). Considerable evidence, reviewed herein, suggests that insulin resistance and the IRS contribute to this unexplained CV risk in patients with T2DM. Accordingly, CV outcome trials with pioglitazone have demonstrated that this insulin-sensitizing thiazolidinedione reduces CV events in high-risk patients with T2DM. In this review the roles of insulin resistance and the IRS in the development of atherosclerotic CV disease and the impact of the insulin-sensitizing agents and of other antihyperglycemic medications on CV outcomes are discussed.

Overview

Integrity signals

Registry

Crossref · 10.1210/er.2018-00141

Cites

340 of 340 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 340 references

Research works printed but not linked: 1

  1. Hsueh, 1999, Insulin signals in the arterial wall, J Cardiol, 84, 21, 10.1016/S0002-9149(99)00353-7 · DOI · Paper page

Cited by

See all 535

Metadata

Authors
Di Pino, A., & DeFronzo, R. A.
Affiliations
  • Diabetes Division, University of Texas Health Science Center and Texas Diabetes Institute, San Antonio, Texas
  • The University of Texas at San Antonio Health Science Center (US)
Corresponding author
DeFronzo, Ralph A
Venue
Endocrine Reviews
Published
2019-05-03
Volume
40
Issue
6
Pages
1447-1467
ISSN
  • 0163-769X (ISSN-L)
  • 1945-7189
OpenAlex
W2945554427
Cited by
535
References
344
Citations by year
2026: 77 · 2025: 117 · 2024: 95 · 2023: 76 · 2022: 89 · 2021: 55 · 2020: 22 · 2019: 4
FWCI
6.54
Type
journal article
Language
en
Open access
Locations
  • Endocrine Reviews (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institutes of Health (DK-24092-38)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
insulin resistance, atherosclerosis, type 2 diabetes, metabolic syndrome, insulin sensitizers, thiazolidinediones, pioglitazone, cardiovascular risk, macrovascular complications, cardiovascular outcome trials, antihyperglycemic medications, cardiometabolic risk factors
MeSH terms
Animals, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Insulin Resistance, Thiazolidinediones, Atherosclerosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents. https://app.cochat.ai/papers/10.1210/er.2018-00141
The paper
Di Pino, A., & DeFronzo, R. A. (2019). Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents. Endocrine Reviews. https://doi.org/10.1210/er.2018-00141

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.